By Frank Prenesti
Date: Wednesday 07 Jan 2026
(Sharecast News) - GSK on Wednesday said its potential chronic hepatitis B treatment had met primary endpoints in two trials that covered 1,800 patients from 29 countries.
| Japan approves GSK treatment for severe asthma | 06-Jan-2026 | ShareCast |
| GSK's COPD treatment approved by Chinese regulat... | 05-Jan-2026 | ShareCast |
| Director Declaration | 02-Jan-2026 | ShareCast |
| Total Voting Rights | 02-Jan-2026 | ShareCast |
| Total Voting Rights | 02-Jan-2026 | ShareCast |
| EC approval of Shingrix PFS | 07-Jan-2026 | 07:05 | RNS |
| Positive phase 3 data for GSK's bepirovirsen | 07-Jan-2026 | 07:00 | RNS |
| Transaction in Own Shares | 07-Jan-2026 | 07:00 | RNS |
| Transaction in Own Shares | 07-Jan-2026 | 07:00 | RNS |
| XP Power Ltd - Notification of Q4 and Full Year ... | 07-Jan-2026 | 07:00 | PR Newswire |
| Questor:Meggitt | 23-Dec-2014 | Telegraph |
| Questor :KCOM | 27-Nov-2014 | Telegraph |
| Questor :Ricardo | 31-Oct-2014 | Telegraph |
| Questor:CSR | 17-Oct-2014 | Telegraph |
| Questor:BAE Systems | 03-Sep-2014 | Telegraph |
| Price | 5,790.05 |
| Change Today | 5.13 |
| % Change | 0.09 % |
| 06-Jan-26 Close | 5,784.92 |
You are here: research